We conducted an open study on efficacy and safety of vinpotropile in patients with initial signs of chronic brain ischemia. Twenty patients, aged from 50 to 78 years, were examined. Seven patients had the diagnosis of discirculatory encephalopathy (DE), I stage, and 13 patients were diagnosed with DE, II stage. Vinpotropile was prescribed in 2 capsules tree times per day during 30 days. At the end of the study (the 30th day), the results of the therapy were assessed as very good or good in 75% of patients. Also, positive changes were seen in the performance on neuropsychological tests: MMSE scores were improved in average by 1,9 point, the mean score in the group being corresponded to normal values. Patients performed better on the Isaac speech activity test. The higher performance on the task and less errors were seen in the proof test that reflected the increase of attention/concentration. Patients showed the significant improvement on a scale that assessed self-rated health, activity and mood. The emotional state was normalized in 50% of patients during the treatment with vinpotropile. No adverse effects were observed.